Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 248-252

  Zeng, Bai Yun ^a   Bukhatwa, Salma ^a   Hikima, Atsuko ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PROTEASOME INHIBITOR; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAPHE NUCLEUS; RAT; REPRODUCIBILITY; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; NEUROGLIA; OLIGOPEPTIDES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UBIQUITIN;

EID: 33746851548     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20932     Document Type: Article

References (18)

1. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44(suppl 1):S72-S84.
2. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-S36.
3. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001;297: 191-194.
4. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-306.
5. McNaught KS, Bjorklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-1441.
6. Hyun DH, Lee M, Halliwell B, et al. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 2003;86:363-373.
7. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
8. McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006;27:530-545.
9. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
10. File SE, Wardill AG. The reliability of the hole-board apparatus. Psychopharmacologia 1975;44:47-51.
11. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press, 1986.
12. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-Synuclein in filamentous inclusions of Lewy bodies From Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-6473.
13. McNaught K, Olanow CW. The proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006;60:243-247.
14. Schapira AHV, Cleeter MWJ, Muddle JR, et al. Proteosomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 2006;60:253-255.
15. Manning-Boǧ AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 2006;60:256-260.
16. Bové J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60: 260-264.
17. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-268.
18. Lang AE, Beal MF. The proteosomal inhibition model of Parkinson's disease: "boon or bust"? Ann Neurol 2006:60: 158-161.